Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia

January 2009
BMC Psychiatry;2009, Vol. 9, p71
Academic Journal
No abstract available.


Related Articles

  • Cortical inhibitory neurons and schizophrenia. Lewis, David A.; Hashimoto, Takanori; Volk, David W. // Nature Reviews Neuroscience;Apr2005, Vol. 6 Issue 4, p312 

    Impairments in certain cognitive functions, such as working memory, are core features of schizophrenia. Convergent findings indicate that a deficiency in signalling through the TrkB neurotrophin receptor leads to reduced GABA (?-aminobutyric acid) synthesis in the parvalbumin-containing...

  • GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia. Volk, David W.; Lewis, David A. // Current Neuropharmacology;Jan2005, Vol. 3 Issue 1, p45 

    Cognitive deficits, including impairments in working memory that have been linked to the prefrontal cortex, are among the most debilitating and difficult to treat features of schizophrenia. Consequently, the identification of potential targets informed by the pathophysiology of the illness is...

  • Mutations in genes regulating neuronal migration predict reduced prefrontal cognition in schizophrenia and bipolar disorder: a preliminary study. Tabares-Seisdedos, Rafael; Escamez, Teresa; Martinez-Gimenez, Juan; Balanza, Vincent; Salazar, Jose; Selva, Gabriel; Rubio, Cristina; Vieta, Eduard; Geijo-Barrientos, Emilio; Martinez-Aran, Anabel; Reiner, Orly; Martinez, Salvador // Annals of General Psychiatry;2006 Supplement 1, Vol. 5, pS157 

    A conference paper about the relationship between neurodevelopmental processes and prefrontal cortex function in schizophrenia and bipolar disorder and genes that regulate neuronal migration is presented. Results reveal that mutations in genes involved in the molecular diagnosis of lissencephaly...

  • Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. Reynolds, G. P.; Beasley, C. L.; Zhang, Z. J. // Journal of Neural Transmission;May2002, Vol. 109 Issue 5/6, p881 

    Summary. Research aimed at understanding the neurotransmitter pathology of schizophrenia has been underway for half a century, with much emphasis on the dopamine system. Although this approach has advanced our understanding of treatment mechanisms, identification of primary dopaminergic...

  • Schizophrenia as a disorder of disconnectivity. Schmitt, Andrea; Hasan, Alkomiet; Gruber, Oliver; Falkai, Peter // European Archives of Psychiatry & Clinical Neuroscience;Nov2011, Vol. 261, p150 

    Schizophrenia is considered as a neurodevelopmental disorder with genetic and environmental factors playing a role. Animal models show that developmental hippocampal lesions are causing disconnectivity of the prefrontal cortex. Magnetic resonance imaging and postmortem investigations revealed...

  • Losing inhibition with ketamine. Seamans, Jeremy // Nature Chemical Biology;Feb2008, Vol. 4 Issue 2, p91 

    Schizophrenia is thought to involve a dysfunction of glutamatergic and GABAergic signaling in the prefrontal cortex, but how these systems interact in the disease has been unclear. Now ketamine, a glutamatergic NMDA receptor antagonist, may provide a mechanism that could link these pathways.

  • Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Yamamura, Satoshi; Ohoyama, Keiko; Hamaguchi, Tatsuya; Kashimoto, Kanae; Nakagawa, Masanori; Kanehara, Shinichi; Suzuki, Dai; Matsumoto, Takuya; Motomura, Eishi; Shiroyama, Takashi; Okada, Motohiro // Psychopharmacology;Oct2009, Vol. 206 Issue 2, p243 

    The atypical antipsychotic drug, quetiapine (QTP), is effective in schizophrenia and mood disorders, but induces seizures compared to typical antipsychotics. To explore the mechanisms of action of QTP, we determined its effects on extracellular levels of norepinephrine, dopamine, serotonin,...

  • Repeated phencyclidine in monkeys results in loss of parvalbumin-containing axo-axonic projections in the prefrontal cortex. Morrow, Bret A.; Elsworth, John D.; Roth, Robert H. // Psychopharmacology;Jun2007, Vol. 192 Issue 2, p283 

    Repeated exposure to the N-methyl- d-aspartate antagonist, phencyclidine, has been shown to result in biochemical and cognitive changes similar to aspects of schizophrenia. Recently, emerging evidence indicated that the symptoms of schizophrenia might result at least in part from dysfunction of...

  • Extrasynaptic GABA receptor activation reverses recognition memory deficits in an animal model of schizophrenia. Damgaard, Trine; Plath, Niels; Neill, Jo; Hansen, Suzanne // Psychopharmacology;Mar2011, Vol. 214 Issue 2, p403 

    Rationale: Schizophrenia is a complex psychiatric disorder comprised of three main classes of symptoms: positive, negative and cognitive symptoms. Currently, no approved treatment exists for the cognitive symptoms. There is thus a great need for research aiming at identifying novel targets for...

  • Opposing Alterations in Excitation and Inhibition of Layer 5 Medial Prefrontal Cortex Pyramidal Neurons Following Neonatal Ventral Hippocampal Lesion. Ryan, Richard T.; Bhardwaj, Sanjeev K.; Tse, Yiu C.; Srivastava, Lalit K.; Wong, Tak Pan // Cerebral Cortex;May2013, Vol. 23 Issue 5, p1198 

    Cognitive abnormalities in schizophrenia reflect deficits in prefrontal cortical function, which could be related to attrition of dendritic structures of prefrontal cortical neurons. Schizophrenia-related prefrontal deficits have been modeled in postpubertal neonatal ventral hippocampal lesioned...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics